Use of beta blockers in various clinical states

Radović, Vesna V

doi:10.2298/mpns1102055r

Cited by 2 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, ruptured atherosclerotic plaque alone or together with vasoconstriction causes a sudden and critical reduction in coronary blood flow, thereby triggering acute thrombosis. A marked reduction in mortality is observed with the use of beta-blockers in patients with acute coronary syndrome (1). Beta-blockers, which are used as the cornerstone in treatment of cardiovascular diseases and reduces oxygen consumption of the myocardium, have been shown to be beneficial as antianginals before acute coronary syndrome in large scale studies including “GRACE and CANRACE” (2).…”

Section: Introductionmentioning

confidence: 99%

Comparison of the effects of metoprolol or carvedilol on serum gamma-glutamyltransferase and uric acid levels among patients with acute coronary syndrome without ST segment elevation

Aşkın

Karakelleoğlu²,

Değirmenci³

et al. 2015

Anatol J Cardiol

View full text Add to dashboard Cite

Objective:Serum gamma-glutamyltransferase (GGT) and uric acid levels measured in patients with acute coronary syndrome without ST segment elevation (NSTEMI) are important in diagnosis and in predicting the prognosis of the disease. There is a limited number of clinical studies investigating the effects of beta-blockers on GGT and uric acid levels in these patients. In our study, we aimed to investigate the effects of beta-blocker therapy on GGT and uric acid levels.Methods:We conducted a randomized, prospective clinical study. Hundred patients with NSTEMI were included in this study, and they were divided into two groups. Fifty patients were administered metoprolol succinate treatment (1 × 50 mg), whereas the remaining 50 patients were administered carvedilol treatment (2 × 12.5 mg). Thereafter, all of the patients underwent coronary angiography. Blood samples were taken at the time of admission, at the 1st month, and 3rd month to detect GGT and uric acid levels.Results:There was no statistically significant difference among the metoprolol or carvedilol groups in terms of the GGT levels measured at the baseline, 1st month, and 3rd month (p=0.904 and p=0.573, respectively). In addition, there was no statistically significant difference among the metoprolol or carvedilol groups in terms of uric acid levels measured at the baseline, 1st month, and 3rd month (p=0.601 and p=0.601, respectively).Conclusion:We found that GGT and uric acid levels did not show any change compared to the baseline values, with metoprolol and carvedilol treatment initiated in the early period in patients with NSTEMI.

show abstract

Section: Introductionmentioning

confidence: 99%